This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wang, D. Articles by Lin, X. Search for Related Content PubMed PubMed Citation Articles by Wang, D. Articles by Lin, X.

BCL6 Represses Smad Signaling in Transforming Growth Factor-β Resistance

¹ Michael E. DeBakey Department of Surgery and ² Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, Texas

Requests for reprints: Michael E. DeBakey, Department of Surgery, Baylor College of Medicine, One Baylor Plaza, Room 139D, Houston, TX 77030. Phone: 713-798-4899; Fax: 713-798-4093; E-mail: xialin{at}bcm.edu.

Key Words: Oncogene • Smad • tumor suppressor • signal transduction • transcription

Transforming growth factor-β (TGF-β) controls a wide spectrum of cellular processes. Deregulation of TGF-β signaling contributes to the pathogenesis of many diseases including cancer and autoimmune diseases. TGF-β signaling is generally mediated through intracellular signal transducers and transcription factors called Smads. Herein, we have identified the oncoprotein BCL6 as a transcriptional corepressor of tumor suppressor Smad4. BCL6 physically interacts with Smad3 and Smad4, disrupts the Smad-p300 interaction, and represses the transcriptional activity of Smad4. In accordance, B-cell lymphoma cells with a high expression level of BCL6 were found to be refractory to TGF-β antiproliferative response, whereas knockdown of BCL6 expression in B-cell lymphoma cells partially restores the TGF-β responses. This study provides strong evidence that overexpression of BCL6 contributes to TGF-β resistance in B-cell lymphoma. [Cancer Res 2008;68(3):783–9]